Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-04-05
2011-04-05
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
07919456
ABSTRACT:
The present invention relates to compositions comprising one or more connective tissue derived polypeptides having a molecular weight of less than 30,000 Da that are capable of tolerising individuals to antigenic components of cartilage and prevent the appearance of and/or treat symptoms of arthritis and other musculoskeletal degenerative conditions. The present invention provides methods for recovering polypeptides having a molecular weight of less than 30,000 Da from connective tissue and having anti-arthritic or anti-inflammatory activity. The present invention further relates to compositions comprising a polypeptide containing an NC4 domain of collagen type IX alpha 1 chain or fragment thereof, having a molecular weight of less than 30,000 Da, where the polypeptide is capable of tolerising individuals to antigenic components of cartilage, preventing the appearance of arthritic symptoms, and/or treating the symptoms of arthritis.
REFERENCES:
patent: 5364845 (1994-11-01), Henderson
patent: 5399347 (1995-03-01), Trentham et al.
patent: 5925736 (1999-07-01), Neff et al.
patent: 6025327 (2000-02-01), Alkayali
patent: 6127523 (2000-10-01), Brewton et al.
patent: 90/08195 (1990-07-01), None
patent: WO 01/93831 (2001-12-01), None
patent: WO 01/93833 (2001-12-01), None
patent: WO 03/062279 (2003-07-01), None
Vaughan-Thomas et al. 2001; EMBL AF419343.
Lu et al., “Different Therapeutic and Bystander Effects by Intranasal Administration of Homologous Type II and Type IX Collagens on the Collagen-Induced Arthritis and Pristane-Induced Arthritis in Rats”, Clinical Immunology (1999); 90(1): 119-127.
Myers et al., “Immunogenicity of Recombinant Type IX Collagen in Murine Collagen-Induced Arthritis”, Arthritis & Rheumatism (2002); 46(4): 1086-1093.
Vasios et al., “Cartilage Type IX Collagen-Proteoglycan Contains a Large Amino-terminal Globular Domain Encoded by Multiple Exons”, The Journal of Biological Chemistry (1988); 263(5): 2324-2329.
Barnett et al., “A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis.” Arthritits Rheum. (1996) 39(4): 623-628.
Chen et al., “Peripheral deletion of antigen-reactive T cells in oral tolerance,” Nature (1995) 376: 177-180.
Cremer et al., “The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease,” J. Mol. Med. (1998) 76: 275-288.
Eyre et al., “Collagen type IX: evidence for covalent linkages to type II collagen in cartilage,” FEB (1987) vol. 200, No. 2, 337-341.
Faria et al., “Oral Tolerance: Mechanisms and Therapeutic Applications,” Advances in Immunology (1999) vol. 73, 153-264.
Holden et al., “Cartilage Oligomeric Matrix Protein Interacts with Type IX Collagen, and Disruptions to These Interactions Identify a Pathogenetic Mechanism in a Bone Dysplasia Family,” The Journal of Biological Chemistry (2001)vol. 276, No. 8, 6046-6055.
J. Kuby, “Immunology, Second Edition” WH Freeman and Company (1994) Chapter 16, pp. 369-391.
Maciewicz et al., “A comparison of four cathepsins (B, L, N and S) with collagenolytic activity from rabbit spleen,” Biochem J. (1988) 256, 433-440.
Needleman et al., “A General Method Applicable to the Search for Similarities in the Amino Acide Sequence of Two Proteins,” J. Mol. Biol. (1970) 48, 443-453.
Pihlajamaa et al., “Characterization of Recombinanat Human Type IX Collagen, association of α chains into homotrimeric and heterotrimeric molecules,” The Journal of Biological Chemistry (1999) vol. 274, No. 32, 22464-22468.
Smith et al., “Measurement of protein using bicinchoninic acid.” Anal Biochem. (1985) 150(1): 76-85.
Smith et al., “Effects of Calcium Pentosan Polysulfate on Joint Inflammation and Pouch Fluid Levels of Leukocytes, Nitric Oxide, and Interleukin-6 in a Rat Model of Arthritis,” Current Therapeutic Research (1999) vol. 60, No. 11, 561-576.
Stegemann et al., “Determination of Hydroxyproline,” Clinica Chimica Acta (1967) 18: 267-273.
Trentham et al., “Effects of oral administration of type II collagen on rheumatoid arthritis.” Science (1993) 261(5129): 1727-1730.
Weiner et al., “Oral tolerance and the treatment of rheumatoid arthritis,” Springer Seminars in Immunopathology (1998) 20: 289-308.
Fassler et al. “Mice lacking α1 (IX) collagen develop noninflammatory degenerative joint disease.”Proc. Natl. Acad. Sci. vol. 91. 1994. pp. 5070-5074.
Haimes et al. “Overexpression of the NC4domain of type IX collagen induces osteoarthritisu in mice.”Inflamm Res. vol. 44. Supplement. 2. 1995. pp. 127-128.
Kojima et al. “Early Degradation of Type IX and Type II Collagen with the Onset of Experimental Inflammatory Arthritis.”Arthritis&Rheumatism. vol. 44, No. 1 2001. pp. 120-127.
European Office Action dated Oct. 20, 2009.
Carlson Karen Cochrane
Merchant & Gould P.C.
Proteobioactives Pty Ltd.
LandOfFree
Connective tissue derived polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Connective tissue derived polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Connective tissue derived polypeptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2726964